Key result
MicraAV shows similar 12-month mortality compared to dual-chamber transvenous pacemakers.
Why the study?
Data directly comparing the AV-synchronous leadless pacemaker MicraAV with dual-chamber transvenous pacemakers after TAVR are limited.
Does an AV-synchronous leadless pacemaker compared to a dual-chamber transvenous pacemaker improve 12-month clinical outcomes in patients with AV block following TAVR?
Cohort (n=74)
No
Does an AV-synchronous leadless pacemaker compared to a dual-chamber transvenous pacemaker improve 12-month clinical outcomes in patients with AV block following TAVR?
In patients requiring pacing for AV block post-TAVR, a leadless pacemaker (MicraAV) showed similar mortality to traditional transvenous dual-chamber pacing but may be associated with increased heart failure rehospitalization and worsening tricuspid regurgitation.
Answers are grounded in this paper and cite their sources.
MicraAV versus DDD after TAVR requires prospective trials; retrospective data leave optimal device choice open.
Background: Data directly comparing the atrioventricular (AV)-synchronous leadless pacemaker (MicraAV) with a dual-chamber transvenous pacemaker (DDD) after transcatheter aortic valve replacement (TAVR) remain limited. Methods: We retrospectively studied patients undergoing pacemaker implantation for advanced or complete AV block within one month after TAVR at a single Japanese center between 2016 and 2025. After exclusions, the primary cohort comprised 74 patients (MicraAV, n = 29; DDD, n = 45). Clinical outcomes were assessed through 12 months, with death treated as a competing event for nonfatal outcomes. Device and echocardiographic parameters were evaluated longitudinally. Results: MicraAV recipients were less frequently female than DDD recipients (48.3% vs. 75.6%, p = 0.025). In the MicraAV and DDD groups, respectively, all-cause mortality was 6.9% and 6.7% (unadjusted HR, 1.12; 95% CI, 0.19–6.68; p = 0.904), heart failure rehospitalization occurred in 17.2% and 4.4% (subdistribution HR, 4.44; 95% CI, 0.86–22.92; p = 0.075), and device-related complications occurred in 6.9% and 4.4% (subdistribution HR, 1.60; 95% CI, 0.23–11.40; p = 0.636). The median MicraAV tracking index was 88.4% [IQR, 66.4–95.1]. No significant group-by-time interactions were observed for device electrical performance or echocardiographic left ventricular parameters. Tricuspid regurgitation worsened over time in the MicraAV group. Conclusions: All-cause mortality and device-related complications were infrequent in both groups, whereas heart failure rehospitalization occurred more frequently in the MicraAV group. Given the small number of events and wide confidence intervals, these findings should be considered exploratory and require confirmation in larger contemporary cohorts.
No takes yet. Share an insight, caveat, or question.
Fukunaga et al. (2026) conducted a cohort in Atrioventricular block following transcatheter aortic valve replacement (n=74). MicraAV vs. Dual-chamber transvenous pacemaker (DDD) was evaluated on All-cause mortality (HR 1.12, 95% CI 0.19-6.68, p=0.904). MicraAV implantation was associated with similar 12-month all-cause mortality compared to dual-chamber transvenous pacemakers.
Synapse has enriched 10 related papers. Consider them for comparative context: